Ramy Younes
Company: Boehringer Ingelheim
Job title: Hepatologist & Clinical Program Leader NASH/Metabolism
Seminars:
Drug Induced Liver Injury (DILI): Impacts on Liver Functionality & Influence on NASH Drug Development 4:30 pm
• Uncovering why DILI is a common liver issue in clinical trials • Revealing the reasons why NASH patients have different level of alteration of liver enzymes • Appreciating the fact that the assessment of DILI in NASH trials requires careful planning and evaluationRead more
day: Day Two